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SUMMARY
A common phenomenon in cancer syndromes is for an individual to have multiple primary
cancers at different sites during his/her lifetime. Patients with Li-Fraumeni syndrome (LFS),
a rare pediatric cancer syndrome mainly caused by germline TP53 mutations, are known to
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have a higher probability of developing a second primary cancer than those with other can-
cer syndromes. In this context, it is desirable to model the development of multiple primary
cancers to enable better clinical management of LFS. Here, we propose a Bayesian recurrent
event model based on a non-homogeneous Poisson process in order to obtain penetrance es-
timates for multiple primary cancers related to LFS. We employed a family-wise likelihood
that facilitates using genetic information inherited through the family pedigree and properly
adjusted for the ascertainment bias that was inevitable in studies of rare diseases by using
an inverse probability weighting scheme. We applied the proposed method to data on LFS,
using a family cohort collected through pediatric sarcoma patients at MD Anderson Cancer
Center from 1944 to 1982. Both internal and external validation studies showed that the
proposed model provides reliable penetrance estimates for multiple primary cancers in LFS,
which, to the best of our knowledge, have not been reported in the LFS literature.
Key words: Age-at-onset penetrance; Familywise likelihood; Multiple primary cancers; Li-
Fraumeni syndrome; Recurrent event model.
1 Introduction
A second primary cancer develops independently at different sites and involves different
histology than the original primary cancer; it is not caused by extension, recurrence or
metastasis of the original cancer (Hayat and others , 2007). Multiple primary cancers (MPC)
is a term for the development of primary cancers more than once in a given patient over
the follow-up time. The occurrence of MPC is becoming more common due to advances
in cancer treatment and related medical technologies, which enable more people to survive
certain cancers. The National Cancer Institute estimated that the US population in 2005
included around 11 million cancer survivors, which was more than triple the number in 1970
(Curtis and others , 2006). Furthermore, surviving a given cancer does not necessarily suggest
a decreased risk of developing another cancer. For example, van Eggermond and others (2014)
reported that the risk of developing a second primary cancer among survivors of Hodgkins
lymphoma is 4.7-fold more than that among the general population. The risk of developing
MPC varies by genetic susceptibility factors as well. For example, Li-Fraumeni syndrome
(LFS), a rare pediatric disease involving higher risk of developing MPC, is associated with
germline mutation in the tumor suppressor gene TP53 (Malkin and others , 1990; Eeles,
1994).
Penetrance is defined as the probability of actually experiencing clinical symptoms of a
particular trait (phenotype) given the status of the genetic variants (genotype) that may
cause the trait. Penetrance plays a crucial role in many genetic epidemiology studies as
it characterizes the association of a germline mutation with disease outcomes (Khoury and
others , 1988). For example, penetrance is an essential quantity for disease risk assessment,
which involves identifying the at-risk individuals and providing prompt disease prevention
strategies. To be more specific, popular risk assessment models often require penetrance
estimates as inputs (Domchek and others , 2003; Chen and Parmigiani, 2007).
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The data that motivated our study is a family cohort of LFS collected through probands
with pediatric sarcoma treated at MD Anderson Cancer Center (MDACC) from January
1944 to December 1982 and their extended relatives (Strong and Williams, 1987; Bondy and
others , 1992; Lustbader and others , 1992; Hwang and others , 2003; Wu and others , 2006).
We use “proband” to denote the affected individual who seeks medical assistance, and based
on whom the family data are then gathered for inclusion in datasets (Bennett, 2011). In the
LFS application, the MPC-specific penetrance is defined as
Pr {(k + 1)th primary cancer diagnosis | TP53 mutation status, history of k cancers} , k = 0, 1, 2, · · ·
(1.1)
If an individual currently has no cancer history (i.e., k = 0), then the MPC-specific penetrance
(1.1) becomes Pr {First primary cancer diagnosis | TP53 mutation status}, which has been
estimated previously by Wu and others (2010) ignoring multiple primary cancers. It shall
therefore lead to more accurate cancer risk assessment in LFS for both cancer survivors
and no-cancer-history individuals by utilizing more detailed individual cancer histories with
MPC.
Few attempts have been made to account for MPC in penetrance estimation. Wang
and others (2010) used Bayes rule to calculate multiple primary melanoma (MPM)-specific
penetrance, based on penetrance estimates for TP53 mutation carriers, the ratio of MPM
patients among carriers and non-carriers, and the ratio of MPM and patients with single
primary melanoma (SPM) among carriers. However, that estimation did not account for
age and other factors that may contribute to variations observed in patients with SPM and
MPM, and relied on previous population estimates of penetrance and relative risk.
MPC can naturally be regarded as recurrent events, which have been extensively studied
in statistics (Cook and Lawless, 2007). However, the MPC-specific penetrance estimation
from LFS data is more challenging than estimations that use the conventional recurrent
event model due to the following reasons. Most individuals (74%) in the LFS family data
have unknown TP53 genotypes, and the LFS data are collected through high-risk probands,
e.g., those diagnosed with pediatric sarcoma at MDACC, resulting in ascertainment biases.
Such bias is inevitable in the study of rare diseases such as LFS as they require an enrichment
of cases to achieve a sufficient sample size.
Shin and others (2018) recently investigated both of the aforementioned problems for the
LFS data under a competing risk framework to provide a set of cancer-specific penetrance
estimates. In particular, they defined the familywise likelihood by averaging the individual
likelihoods within the family over the missing genotypes, which is possible since the exact dis-
tribution of missing genotypes is available according to the Mendelian law of inheritance. The
familywise likelihood can minimize the efficiency loss since the missing genetic information is
taken into account in its calculation. They also proposed to use the ascertainment-corrected
joint (ACJ) likelihood (Iversen and Chen, 2005) to correct the ascertainment bias for the
LFS data.
In this article, we propose a Bayesian semiparametric recurrent event model based on a
non-homogeneous Poisson process (NHPP)(Brown and others , 2005; Weinberg and others ,
2007; Cook and Lawless, 2007) in order to reflect the age-dependent and time-varying nature
3
of the cancer occurrence rate in LFS. Our preliminary analysis justifies the NHPP model for
the LFS data. We develop what we call the ascertainment-corrected familywise likelihood for
the proposed NHPP model and estimate the parameters using a Markov chain Monte Carlo
(MCMC) algorithm. Then, we provide a set of MPC-specific penetrances for LFS, which, to
the best of our knowledge, have never been reported in the literature.
The rest of this paper is organized as follows. In Section 2, we introduce the LFS family
data that motivate this study. In Section 2.2, we provide an explorative analysis for the data
to justify our approach. In Section 3, we propose a semiparametric recurrent event model for
MPC based on NHPP. In Section 4, we describe in detail how to construct the familywise
likelihood, including the ascertainment bias correction. We provide the posterior updating
scheme via MCMC in Section 5. We describe a simulation study in Section 6. In Section
7, we apply the proposed method to the LFS data and obtain the estimated age-at-onset
MPC-specific penetrances. We also carry out both internal and external validation analyses.
Our final discussion follows in Section 8.
2 Preliminary Analysis of the LFS Data
2.1 LFS Data Summary
The pediatric sarcoma cohort data from MDACC consists of 189 unrelated families, with 17
of them being TP53 mutation positive families in which there is at least one TP53 mutation
carrier, and 172 being negative ones with no carrier (See Appendix G in Supplementary
Materials). The TP53 status was determined by PCR of TP53 exonic regions. Ascertainment
is carried out through identification of a proband who has a diagnosis of pediatric sarcoma
and who introduces his/her family into the data collection. After a family was ascertained,
family members were contacted regularly and continually recruited into the study over 1944
to 1982. Blood samples from members of the family were collected whenever available.
The genetic testing of TP53 was performed on these blood samples, which constitutes the
genotype data. Among a total of 3,706 individuals, 964 of them had TP53 testing results.
The age at the diagnosis of each invasive primary tumor for each individual was recorded.
The follow-up periods for each family ranges from 22-62 years starting from the acertainment
date of probands. Among 570 individuals with a history of cancer, a total of 52 had been
diagnosed with more than one primary cancer (Table 1). Further details on data collection
and germline mutation testing can be found in Hwang and others (2003) and Peng and others
(2017).
2.2 Exploratory analysis
We first carry out a preliminary analysis of the LFS data to propose a model that correctly
reflects the nature of the data. For simplicity in this analysis, we ignore the family structure.
Let (T, V,G, S) be a set of data given for an arbitrary individual. For an individual who
experiences K,K = 0, 1, · · · primary cancers, T = (Tk; k = 0, · · · , K) denotes the individuals
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age at diagnosis of the kth primary cancer, with T0 = 0; V is the censored age at which the
individual is lost to follow-up, which is assumed to be independent of all Tk’s; G denotes the
genotype variable, coded as 1 for germline mutation and 0 for wildtype, with a large number
of missing values as shown in Table 1; and S denotes the individuals sex, coded as 1 for male
and 0 for female.
In the analysis of MPC, a primary objective is to model the time to the next cancer given
the current cancer history. We let Wk = Tk − Tk−1 denote the kth gap time between two
adjacent primary cancers, where k = 1, 2, · · · . In analyzing the serial gap times W1,W2, · · · ,
the censoring time V , although independent of Tk, can be dependent on Wk when the Wk’s
are not independent (Lin and others , 1999). This is often referred to as dependent censoring
in the literature. Dependent censoring makes it inappropriate to fit marginal models for the
kth gap times Wk(k ≥ 2). For example, Cook and Lawless (2007) showed that ignoring
dependent censoring can lead to underestimation of the survival functions of the second and
subsequent gap times.
To check the dependent censoring, we compute the correlation between W1 and W2 using
Kendall’s τ . Table 1 shows that values of Wk(k ≥ 3) are rarely observed in the LFS data,
and we therefore exclude them in the analysis. Noting that both W1 and W2 can be censored,
we use the inverse probability-of-censoring weighted (IPCW) estimates of Kendall’s τ after
adjusting for the induced dependent censoring issue (Lakhal-Chaieb and others , 2010). In
the analysis, we exclude probands who are the index person for family ascertainment. More
details about IPCW estimates of Kendall’s τ can be found in Appendix A (Supplementary
Materials). Finally, the estimated IPCW Kendall’s τ = −0.017 (jackknife estimation of the
standard error =0.005), which indicates a statistically significant, but very weak correlation
between the two gap times within individuals. We have further calculated Kendall’s τ within
subgroups of mutation carriers and noncarriers. Neither of the subgroup τ estimates was
significantly different from zero.
We computed Kaplan-Meier estimates of survival functions S1(t) = Pr(W1 > t) and
S2(t) = Pr(W2 > t), stratified by genotype (See Appendix G in the Supplementary Mate-
rials). The risk set used for calculating S2(t) considers only patients with a single primary
cancer (SPC) and MPC starting from the first cancer, while S1(t) includes all individuals.
For both TP53 mutation carriers and non-carriers or untested individuals, the lengths of
the first and second gap times are not identically distributed, with the first gap time sig-
nificantly longer than the second one. This suggests a time trend in the process where the
rate of event occurrence increases with age. Moreover, the mutation carriers appear to have
different length distributions for wildtype and untested individuals. This empirical differ-
ence in successive survival also suggests the importance of providing subgroup-specific and
MPC-specific penetrance.
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3 Model
3.1 Semiparametric recurrent event model for MPC
Viewing the MPC as recurrent events that occur over time, we employ a counting process to
model the MPC.
Let {N(t), t ≥ 0} be the number of primary cancers that an individual experiences by age
t. The intensity function λ(t|H(t)) that characterizes the counting process N(t) is defined as
λ(t|H(t)) = lim
4t→0
Pr{N(t+4t)−N(t) > 0|H(t)}
4t (3.1)
where H(t) denotes the event history up to time t−, i.e., H(t) = {N(s), 0 ≤ s < t}, with t−
being a time infinitesimally before t (Cook and Lawless, 2007; Ning and others , 2015).
For the LFS data, we incorporate a covariate X(t) = {G,S,G × S,D(t), G × D(t)}T
into the Poisson process model, where D(t) is a time-dependent, but periodically fixed MPC
variable that is coded as 1 if t > T1 and 0 otherwise. We propose the following multiplicative
model for the conditional intensity function given X(t) as
λ(t|X(t), ξi) = ξiλ0(t) exp(βTX(t)), (3.2)
where β denotes the coefficient parameter that controls effect of covariate X(t) on the inten-
sity and λ0(t) is a baseline intensity function. Here, ξi is the ith family-specific frailty used to
account for the within-family correlation induced by non-genetic factors that are not included
in X(t). We remark that ξi allows us to relax the assumption that the disease histories are
conditionally independent given the genotypes. We consider the gamma frailty model that
assumes ξ1, · · · , ξI iid∼ Gamma(φ, φ), where I denotes the number of families. The gamma
frailty model has been used as a canonical choice (Duchateau and Janssen, 2007) due to the
mathematical convenience. Recalling that E(ξi) = 1 and var(ξi) = φ
−1, a large value of φ
indicates that the within-family correlation is negligible, and we can drop the frailty term to
obtain a more parsimonious model.
There are several choices for the baseline intensity function. Constant or polynomial base-
line intensity can be used due to its simplicity, but it may be too restrictive in practice. As an
alternative, the piecewise constant model has been widely used due to its flexibility. However,
the selection of knot points may be subjective, and it always produces a non-smooth function
estimate, which is not desired in some applications. We propose to employ Bernstein polyno-
mials to approximate the cumulative baseline intensity function, Λ0(t) =
∫
λ0(u)du, which is
monotonically increasing. Bernstein polynomials are widely used in Bayesian nonparametric
function estimation with shape constraints. Assuming t ∈ [0, 1] without loss of generality,
Bernstein polynomials of degree M for Λ0(t) are BM(t; Λ0) = γ
TFM(t), where the known pa-
rameter vector γ = (γ1, · · · , γM) with γm = Λ0(mM )−Λ0(m−1M ),m = 1, · · · ,M and Λ0(0) = 0;
and FM(t) = (FM(t, 1), · · · , FM(t,M))T , with FM(t,m) being the beta distribution function
with parameters m and M − m + 1 evaluated at t (Curtis and Ghosh, 2011). We restrict
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γm ≥ 0,m = 1, · · · ,M to have Λ0 monotonically increasing. The Bernstein-polynomial
model for λ0(t) is then obtained by
λ0(t) ≈ d
dt
BM(t; Λ0) = γ
T fM(t), (3.3)
where fM(t)
T = (fM(t, 1), · · · , fM(t,M))) denotes the beta density with parameters m and
M −m+ 1 evaluated at t.
A large value of M provides more flexibility to model the shape of baseline rate function,
but at the cost of increased computations. Gelfand and Mallick (1995) empirically showed
that a relatively small value of M works well in practice, and we assume M = 5 in the
upcoming analyses.
Finally, the proposed semi-parametric model for the intensity function of NHPP is given
by
λ(t|X(t), ξi) = ξiγT fM(t) exp{βTX(t)}.
3.2 MPC-specific penetrance
The MPC-specific age-at-onset penetrance defined in (1.1) is equivalently rewritten as
Pr(Wk+1 ≤ w|Tk,X(t)), (3.4)
which is identical to Pr(Wk+1 ≤ w|Tk,X(Tk)) since D(t) is periodically fixed. The MPC-
specific penetrance (3.4) is then obtained by marginalizing out the random frailty ξ as follows:
Pr(Wk+1 ≤ w|Tk = tk,X(tk)) = 1−
∫ ∞
0
exp
(
−
∫ tk+w
tk
λ(u|X(u), ξ)du
)
f(ξ|φ)dξ
= 1−
(
φ
φ+
∫ tk+w
tk
λ(u|X(u))du
)φ
,
where f(ξ|φ) is the gamma density function of the frailty ξ given φ, and λ(t|X(t)) =
λ0(t) exp{βTX(t)}.
4 Computing Likelihood
In this work, the computing likelihood is not trivial due to a large number of missing geno-
types and the ascertainment bias. In this section, we propose an ascertainment-bias-corrected
familywise likelihood to tackle these issues.
Let vij and Kij respectively denote the censoring time and the total number of primary
cancers developed for individual j = 1, · · · , ni from family i = 1, · · · , I. Suppose we are
given a set of data (tij, vij, gij, sij), where tij = {tij,k : k = 1, · · · , Kij}T and gij and sij are
the observed genotype and sex, respectively. Given the data, we can easily define the observed
version of D(t) denoted by dij(t) as 1 if t > tij,1 and 0 otherwise, and xij(t) = {gij, sij, gij ×
sij, dij(t), gij × dij(t)}T .
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4.1 Individual likelihood
Let tij,0 = 0 and vij ≥ tij,Kij , conditioning on ξi, the likelihood contribution of the kth event
since the (k − 1)th event is
λ(tij,k|xij(tij,k), ξi) exp
(
−
∫ tij,k
tij,k−1
λ(u|xij(u), ξi)du
)
, (4.1)
(Cook and Lawless, 2007).
Let xij = {xij(tij,k), k = 1, · · · , Kij} and θ = (β,γ, φ) denote the parameter vectors of
interest. Given ξi, the likelihood of the jth individual of the ith family with primary cancer
events hij = (tij, vij), denoted by Pr(hij|xij,θ, ξi) is
Pr(hij|xij,θ, ξi) ∝

Kij∏
k=1
λ(tij,k|xij(tij,k), ξi)
×
exp
−
Kij∑
k=1
∫ tij,k
tij,k−1
λ(u|xij(u), ξi)du
× exp
{
−
∫ vij
tij,Kij
λ(u|xij(u), ξi)du
}
.
(4.2)
4.2 Familywise likelihood
Tentatively assuming that the covariates xij are completely observed for every individual, the
likelihood for the ith family is simply given by
∏ni
j=1 Pr(hij|xij,θ, ξi). However, in the LFS
data, most individuals have not undergone testing for their TP53 mutation status. For sim-
plicity, we partition the covariate vector xij = {gij,gcij}, where gij and gcij denote the covari-
ates that are related and unrelated to the genotype gij, respectively. Let hi = (hi1, · · · ,hini),
gi = (gi1, · · · ,gini) and gci = (gci1, · · · ,gcini). Due to a large number of family members with-
out genotype information, gi, we further introduce gi,obs and gi,mis to respectively denote the
observed and missing parts of genotype vector gi, i.e., gi = {gi,obs,gi,mis}. The familywise
likelihood for the ith family is naturally defined by
Pr(hi|gi,obs,gci ,θ, ξi), (4.3)
while its evaluation is not trivial since hi1, · · · ,hini are correlated through gi,mis.
To tackle this issue, we employ Elston-Stewart’s peeling algorithm to recursively calculate
(4.3) (Elston and Stewart, 1971; Lange and Elston, 1975; Fernando and others , 1993). Let us
suppress the conditional arguments in (4.3) except gi,obs for simplicity. The peeling algorithm
is developed to evaluate the pedigree likelihood Pr(hi), not Pr(hi|gi,obs), accounting for the
probability distribution of genotype configurations of all family members (e.g., 3n genotype
configurations for one gene and n family members). It proceeds by recursively partitioning
a large family into smaller ones. An illustrative example of the peeling algorithm for the
familywise likelihood evaluation is given in Appendix B (Supplementary Materials). Notice
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that if there is no genotype observed, i.e., gi = gi,mis, then (4.3) can be evaluated by directly
applying the peeling algorithm. We have made slight modification on the peeling algorithm
to include known genotype information of some family members in our data (Shin and others ,
2018).
4.3 Ascertainment bias correction
Ascertainment bias is inevitable in studies of rare diseases like LFS because the datasets
are usually collected from a high-risk population. For example, our LFS dataset is ascer-
tained through proabands diagnosed at LFS primary cancers such as pediatric sarcoma at
MD Anderson Cancer Center, and therefore has oversampled LFS primary cancer patients.
Such ascertainment must be properly adjusted to generalize the corresponding results to the
population, for which the familywise likelihood (4.3) alone is not sufficient.
We propose to use an ascertainment-corrected joint (ACJ) likelihood (Kraft and Thomas,
2000; Iversen and Chen, 2005). Introducing an ascertainment indicator variable Ai = 1 that
takes 1 if the ith family is ascertained and 0 otherwise, the ACJ likelihood for the ith family
is given by
Pr(hi,gi,obs|gci ,θ, ξi,Ai = 1) ∝
Pr(hi|gi,obs,gci ,θ, ξi)
Pr(Ai = 1|gci ,θ, ξi)
. (4.4)
That is, the ACJ likelihood corrects the ascertainment bias by inverse-probability weighting
(4.3) by the corresponding ascertainment probability. Now, the ascertainment probability,
the denominator in (4.4), is the likelihood contribution of the proband, computed as follows:
Pr(Ai = 1|gci ,θ, ξi)
=
∑
g∈{0,1}
[
λ(ti1,1|xi1(ti1,1; g), ξi) exp
{
−
∫ ti1,1
0
λ(u|xi1(u), ξi)du
}]
Pr(Gi1 = g|gci1), (4.5)
where xi1(t; g) = {g, si1, g × si1, di1(t), g × di1(t)}T for the proband in family i. Notice this
likelihood is marginalized over genotype since the genotype information for the proband is
not available when the ascertainment decision is made. In general, the covariate specific
prevalence Pr(Gi1 = g|gci1) is assumed to be known. In our LFS application, we assume
the TP53 mutation prevalence is independent of all non-genetic variables and therefore the
conditional prevalence is equal to the unconditional prevalence Pr(Gi1 = g) for a general
popoulation, which can be calculated from the mutated allele frequency denoted by ψA:
Pr(Gi1 = 0) = (1 − ψA)2 and Pr(Gi1 = 1) = 1 − (1 − ψA)2. Here ψA = 0.0006 for TP53
mutations in the Western population (Lalloo and others , 2003).
Finally, the ACJ familywise likelihood for the LFS data is then given by
Pr(H,Gobs|Gc,θ, ξ,A) ∝
I∏
i=1
Pr(hi|gi,obs,gci ,θ, ξi)
Pr(Ai = 1|gci ,θ, ξi)
where H = (h1, · · ·hI), Gobs = (g1,obs, · · · ,gI,obs), Gc = (gc1, · · · ,gcI), and ξ = (ξ1, · · · , ξI),
and A = (A1, · · · ,AI).
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5 Posterior Sampling through MCMC
We set an independent normal prior for β where β ∼ N(0, σ2I) where 0 and I denote a
zero vector and an identity matrix, respectively, and σ = 100 for vague priors. We assign
nonnegative flat priors for γ ∼ Gamma(0.01, 0.01) for the baseline intensity. We assume a
gamma prior for φ ∼ Gamma(0.01, 0.01). The joint posterior distribution of (θ, φ, ξ) is
Pr(θ, φ, ξ|H,Gobx,Gc,A) ∝ Pr(H,Gobs|Gc,θ, ξ,A) Pr(θ) Pr(ξ|φ) Pr(φ). (5.1)
where Pr(θ) and Pr(φ) denote prior distributions, and Pr(ξ|φ) is a frailty density that we
assume to follow gamma distribution. We use a random walk Metropolis-Hastings-within-
Gibbs algorithm to generate 100,000 posterior estimates in total, with the first 5,000 as
burn-in. Details about the algorithm steps, R code and convergence diagnostics can be
found in the Appendix C (Supplementary materials).
6 Simulation Study
We simulated family history data containing patients with single and multiple primary can-
cers as follows:
1. We first simulated the genotype of the proband by G ∼ Bernoulli(0.001), based on
which we generated the first and second gap times, W1 and W2, from the exponential
distribution with the rate parameter being
λ(t|G,D) = ξλ0(t) exp(β1G+ β2D), (6.1)
where D = 0 for W1 and D = 1 for W2. We set a constant baseline λ0(t) = 0.0005, and
β1 = 6 and β2 = 1. We simulated ξ ∼ Gamma(φ, φ) with φ = 1. The two gap times
were then compared to censoring time generated by V ∼ Exponential(0.5) to deter-
mine the event indicator. To mimic the ascertainment procedure, for the family data
simulation, we retained only the probands with at least one primary cancer observed.
2. Given the proband’s data, we generated his/her family data for three generations. The
complete pedigree structure for the simulation is depicted in Appendix G (Supplemen-
tary materials). We set the genotype of all family members as G = 0 if the proband
was a non-carrier. If the proband was a TP53 mutation carrier, one of his/her parents
was randomly set as a carrier, and the proband’s siblings and offsprings were set inde-
pendently as carriers with a probability of 0.5. The offspring of the proband’s siblings
were also randomly set as carriers with a probability of 0.5 if the proband’s siblings
were carriers. To mimic the scenario of the rate of a rare mutation such as that of the
TP53 gene, all family members with non-blood relationships with the proband were
set as non-carriers.
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3. We simulated the first two gap times and the cancer event indicators for the probands’
relatives as we did for the probands. We simulated a total of 100 such families, each
of which had 30 family members. To mimic the real scenario in which genotype data
are not available for a majority of family members, we randomly removed 70% of the
genotype information from non-proband family members.
We applied the proposed methods to the simulated data. We generated 5000 posterior
samples from the MCMC algorithm, with the first 1000 as burn-in, and checked that the
MCMC chains converged well. Simulation results based on 100 independent repetitions are
summarized in Figure 1. The proposed method can successfully recover the true parameters.
See the top panel for the comparison to a model without frailty, in terms of the root mean
squared error and absolute bias, and the bottom panel for the comparison to a model without
ascertainment bias correction.
7 Case Study
We applied our method to the LFS data (Section 2.2) and estimated the parameters using
the MCMC algorithm as described in Section 5. We performed cross-validation, in which we
compared our prediction of the 5-year risk of developing the next cancer given the individual’s
cancer history and genotype information with the observed outcome, based on our penetrance
estimates. We also compared our penetrance results with population estimates and the results
in previous studies on TP53 penetrance.
7.1 Model fitting
We fit our model to the LFS data up to the second cancer event due to the limited number of
individuals with three or more primary cancers in the dataset (Table 1). Our model contains
three relevant covariates: genotype, sex, and cancer status at time t, respectively denoted by
G, S, and D(t). We also included two interaction effects on genotype.
We applied the proposed method to the entire dataset to obtain penetrance estimates for
SPCs and MPCs given the TP53 mutation status. We first conducted a sensitivity analysis,
which showed that the penetrance estimates are not overly sensitive to the choice of priors.
The results of the sensitivity analysis are provided in Appendix D (Supplementary materials).
We then computed the deviance information criterion (DIC) to identify the best set of
covariates. We compare five different combinations of G,S, and D(t). We observe that the
simplest model with {G,S,D(t)} achieves the minimum DIC value. However, we decided to
select the second best model in terms of the DIC, with {G,S,D(t), G× S,G×D(t)} as our
final model since it has been reported that cancer status has different effects on cancer risk
for mutation carriers and non-carriers (van Eggermond and others , 2014; Mai and others ,
2016). All posterior estimates of the model generated from the MCMC algorithm converged
well and had reasonable acceptance ratios. See Appendix E (Supplementary materials) for
the model comparison results.
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Table 2 contains summaries of the posterior estimates for both the frailty and no-frailty
models. We observe that the variance of frailty, φ−1, is estimated to be quite small, which
indicates that the no-frailty model may be preferred. It turns out that both models produce
nearly identical penetrance estimates (see Appendix E in the Supplementary Materials), and
we decide to use the no-frailty model to analyze the LFS data. The genotype has dominant
effects on increasing cancer risk, both through a main effect and through interaction with
the cancer history, as expected from the exploratory analysis (Section 2.2).
Figure 2 compares penetrance estimates at different ages for females and males, respec-
tively stratified by genotype. As expected, TP53 mutation has a clear effect on the increase
of cancer risk, especially when the individual has a recent history of cancer. For an individual
without a TP53 mutation, a history of cancer also has a positive effect on increasing the risk
of developing subsequent cancer.
Wu and others (2010) estimated TP53 penetrance for the first primary cancer only from
six pediatric sarcoma families, a subset of our LFS dataset. Figure 2 shows that, for mutation
carriers, this age-at-onset TP53 penetrance estimate aligns with those for SPC in our model
but is slightly increased at an older age. Such consistency with a published analysis validates
the performance of our model in real data. Another validation is when we compared our
estimates for non-carriers to population estimates from the Surveillance, Epidemiology, and
End (SEER) Results program (LAG and others , 2008), they also align well (Figures 2c and
d, more consistent in males than in females).
7.2 Cancer risk prediction
We assessed the ability of our model to predict cancer risk prediction using 10-fold cross-
validation. We randomly split the 189 families into 10 portions and repeatedly fit our model
to the 9 of the portions of all the families to estimate the penetrance, based on which we made
predictions using the remaining 1 portion of the data. The individuals used for prediction
are those who have known genotype information. We removed the probands because they
were not randomly selected for genotype testing. We rolled back five years from the age of
diagnosis of cancer or the censoring age. Based on the rolled-back time, we then calculated
a 5-year cumulative cancer risk. We made two types of risk predictions that are of clinical
interest. In the first scenario, we predicted the 5-year risk of developing a cancer given that
the individual has no history of cancer (affected versus unaffected). In the second scenario,
we predicted the risk of developing the next cancer when the individual had developed cancer
previously (SPC versus MPC). We combined these results with those from the 10-fold cross-
validation together and evaluated them using the receiver operating characteristic (ROC)
curves. To assess the variation in prediction caused by data partitioning, we performed
random splits for cross-validation 25 times. Figure 3 shows the risk prediction results from
each random split. The median area under the ROC curve (AUC) is 0.804 for predicting the
status of being affected by cancer versus the status of not being affected by cancer, given that
the individual has no history of cancer. The median AUC is 0.749 for predicting the status
of the next cancer when the subject has had one primary cancer. The validation showed that
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the model performance is robust to random splits in cross-validation.
8 Discussions
To our knowledge, this is the first attempt to estimate MPC-specific penetrance for TP53
germline mutation to include family members with unknown genotype information, which
will, in turn, substantially improve the sample size and power of a study. In our LFS study,
the increases in the number of cancer patients used in the analysis are 33% (from 27 to
40) for MPCs, and 47% (from 274 to 518) for the control group of SPCs. We developed
a novel NHPP and incorporated it with a familywise likelihood so that it can model MPC
events in the context of a family, while properly accounting for age effects and time-varying
cancer status. We applied a Bayesian framework to estimate the unknown parameters in
the model. We also adjusted for ascertainment bias in the likelihood calculation so that our
penetrance estimates can be compared to those generated from the general population. Our
new method provides a flexible framework for the penetrance estimation of MPC data, and
shows reasonable predictive performance of cancer risk. As the number of patients with MPC
continues to rise in the general population, our method will be useful to predict subsequent
cancers and to assist in clinical management of the disease.
Some possible extensions remain. First, we restricted our analysis up to the second pri-
mary cancer because of the limited power in the LFS dataset. This makes our penetrance
estimation unsuitable for individuals with a history of more than two cancers. It is straight-
forward to extend our model to account for three or more cancers if we have such cases for
each subpopulation.
Second, the occurrence of primary cancers may depend on other factors such as cancer
treatment. For example, radiotherapy can damage normal cells in tumor-adjacent areas
and is associated with excessive incidence of secondary solid cancers (Inskip and Curtis,
2007). Our model can include additional covariates to adjust for such dependency between
successive events. However, the availablity of reliable data on radiotherapy is scarce and we
have shown here that the current model can have reasonable predictive performance even
without incorporating treatment factors.
Third, because the correlation between the first two gap times in the real data is very
small, the recurrent event model we used in this study does not explicitly consider such an
association. For future datasets that exhibit a stronger level of correlation between the gap
times, we would expect the predictive performance for the second or subsequent primary can-
cers to be improved by properly utilizing such correlation information (i.e., through Bayesian
parametric copula models for sequential gap time analyses (Meyer and Romeo, 2015)).
Finally, in MPC studies, there usually exist multiple types of cancer. In our LFS study,
even though our genetic background is simple, TP53 germline mutations, the presentation
of cancer outcomes is diverse. LFS is characterized by occurrence of many different cancer
types, such as sarcoma, breast cancer and lung cancer. Patients with MPC are thus subject
to the competing risk of multiple types of cancer. In our current model, we pool together
all cancer types and do not address the onset of second primary cancer at any specific site.
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As we collect more datasets on LFS from multiple clinics to increase our sample size, future
work will include extending our methodology to provide MPC-specific and cancer-specific
penetrance estimation.
Finally, we provide an illustration of our method in Appendix F (Supplementary Materi-
als). The associated example dataset and results, and all of the source code, are available at
http://github.com/wwylab/MPC.
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Table 1: Number of primary cancers in the LFS dataset
Number of primary cancers Gender Wildtype Mutation Unknown
0 Male 295 9 1276
Female 341 8 1207
1 Male 105 25 139
Female 121 23 105
2 Male 3 9 8
Female 3 12 5
3 Male 0 3 0
Female 0 2 2
4 Male 0 2 0
Female 0 1 0
5 Male 0 0 0
Female 0 1 0
7 Male 0 0 0
Female 0 1 0
Total number of individuals 868 96 2742
Total number of cancer patients 232 79 259
Total number of MPC patients 6 31 15
Table 2: Summary of posterior estimates. sd, standard deviation.
coefficient
Frailty No Frailty
Median sd 2.5% 97.5% Median sd 2.5% 97.5%
βG 3.516 0.256 3.068 3.953 3.288 0.223 2.871 3.687
βS 0.027 0.115 -0.189 0.232 0.027 0.118 -0.187 0.241
βG×S -0.332 0.246 -0.809 0.139 -0.354 0.239 -0.817 0.106
βD(t) -0.380 0.363 -1.152 0.259 -0.197 0.336 -0.929 0.389
βG×D(t) 0.716 0.429 -0.070 1.601 0.700 0.402 -0.033 1.548
φ 5.883 1.695 3.427 9.855 Not Available
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Frailty No Frailty
β1 0.1960 (0.0586) 0.1976 (0.0279)
β2 0.3398 (0.0421) 0.4332 (0.3083)
λ0 0.0001 (0.0001) 0.0001 (0.0001)
φ 1.6360 (1.5135) Not Available
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Figure 1: Simulation Results: The top panel shows boxplots of the estimates from 100
independent with the corresponding true values depicted in red dashed line. The Bottom
panel reports root mean squared errors and absolute biases (in parenthesis) of the estimates
from the models with and without frailty term. The truths for the simulation data are:
β1 = 6, β2 = 1, λ0 = 0.0005
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Figure 2: Age-at-onset penetrances of SPC and MPC for (a) female mutation carriers, (b)
male mutation carriers, (c) female mutation non-carriers and (d) male mutation non-carriers.
The shaded area is the 95% credible bands. Note the y-axis scales between carriers and
non-carriers are different. Notations: G = 1, mutation carriers; S = 1, male; T1 = 20,
the first primary cancer diagnosed at age 20. “LFS penetrance” denotes an estimate for
Pr {First primary cancer diagnosis | TP53 mutation status} that was previously published
using a subset of our LFS dataset without considering the onset of multiple primary cancers.
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Figure 3: ROC of the 5-year risk of developing the second primary cancer in the LFS dataset.
The dotted lines denote the ROC curves for 25 random splits of the data, each undergone a 10-
fold cross-validation. The solid lines denote the median ROC curves. Affected vs. Unaffected,
prediction of developing a cancer given that the individual has no history of cancer; MPC vs.
SPC, prediction of developing the next cancer given that the individual has had one primary
cancer (SPC). Sample size: n(Affected)=123, n(Unaffected)=643, n(MPC)=21, n(SPC)=33.
Abbreviation: se, standard error.
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APPENDIX
A Computation of IPCW Kendall’s τ
Letting (X1, Y1) and (X2, Y2) be two independent realizations of (X, Y ), the first and
second gap times, and letting ψ12 = I{(X1−X2)(Y1−Y2) > 0}− I{(X1−X2)(Y1−Y2) < 0}
indicate the concordant/discordant status of the pair, the Kendall’s τ (Gibbons and Kendall,
1990) can be estimated from uncensored bivariate data {(Xi, Yi), i = 1, . . . , n} by(
n
2
)−1∑
i<j
ψij
. In the presence of censoring events (VX , VY ), respectively related to the two gap times,
the estimation of τ can only be based on orderable pairs. Let one observation be denoted
as (X˜, Y˜ , δX , δY ), where X˜ = min(X, VX), Y˜ = min(Y, VY ), δX = I(X < VX) and δY =
I(Y < VY ). Oakes (1982) showed that the pair (i, j) is orderable if {X˜ij < V˜Xij , Y˜ij < V˜Yij},
where X˜ij = min(Xi, Xj), Y˜ij = min(Yi, Yj), V˜Xij = min(VXi, VXj), and V˜Yij = min(VY i, VY j).
Letting Lij be the indicator of this event, and pˆij be an estimator of the probability of being
orderable pij = Pr(VX > X˜ij;VY > Y˜ij|X˜ij, Y˜ij), Lakhal-Chaieb and others (2010) proposed
the weighted estimate as
τˆm =
(∑
i<j
Lij
pˆij
)−1∑
i<j
Lijψij
pˆij
To identify orderable pairs and estimate the corresponding pij, Lakhal-Chaieb and others
(2010) showed that Lij can be reduced to that Xi and Xj being uncensored, Y˜ij being
observed, and that {VXi > Xi + Y˜ij;VXj > Xj + Y˜ij}. The conditional probability of a pair
being orderable is then
pij = Pr{VXi > Xi + Y˜ij;VXj > Xj + Y˜ij|Xi, Xj, Y˜ij}
= G(Xi + Y˜ij)×G(Xj + Y˜ij)
The probability is estimated by
pˆij = Gˆ(Xi + Y˜ij)× Gˆ(Xj + Y˜ij)
where Gˆ(.) is the Kaplan-Meier estimator of G(.) based on {(X˜k + Y˜k, 1− δYk), k = 1, · · · , n}.
The standard error of the Kendall’s τ is estimated by the jackknife technique.
B An example of using the peeling algorithm to calcu-
late the familywise likelihood
Supplementary Figure 1 shows an example of a hypothetical family with 3 generations.
Without loss of generality, we assume that gTobs = (g1, g4) and let g
T
mis = (g2, g3, g5, g6, g7)
2
and HT = (h1, · · · , h7) denote vectors of the unknown genotypes and the cancer history
of the family, respectively. The peeling algorithm peels through the family by considering
individuals 1, 2, 3 as anterior and individuals 5, 6, 7 as posterior of individual 4. We can
then compute the family-wise likelihood Pr(h|gobs) as follows:
Pr(h|gobs)
= Pr(h4|gobs)× Pr(h1, h2, h3|gobs)× Pr(h5, h6, h7|gobs)
= Pr(h4|g4)× Pr(h1|g1) · Pr(h2, h3|g1, g4)× Pr(h5, h6, h7|g1, g4)
= Pr(h4|g4)× Pr(h1|g1) ·
[∑
g2
Pr(h2|g2) Pr(h3|g1, g2, g4) Pr(g2|g1, g4)
]
×
[∑
g5
Pr(h5|g5) Pr(h6, h7|g1, g4, g5) Pr(g5|g1, g4)
]
= Pr(h4|g4)× Pr(h1|g1) ·
[∑
g2
Pr(h2|g2) Pr(g2|g4)
{∑
g3
Pr(h3|g3) Pr(g3|g1, g2, g4)
}]
×
[∑
g5
Pr(h5|g5) Pr(g5)
{∑
g6
Pr(h6|g6) Pr(h7|g4, g5) Pr(g6|g4, g5)
}]
= Pr(h4|g4)× Pr(h1|g1) ·
[∑
g2
Pr(h2|g2) Pr(g2|g4)
{∑
g3
Pr(h3|g3) Pr(g3|g1, g2, g4)
}]
×
[∑
g5
Pr(h5|g5) Pr(g5)
{∑
g6
Pr(h6|g6) Pr(g6|g4, g5)
(∑
g7
Pr(h7|g7) Pr(g7|g4, g5)
)}]
.
All probabilities in the last equation are straightforward to compute when the mode of
inheritance is known.
C Bayesian estimation procedure
In this study, we used the MCMC algorithm to generate posterior distributions for model
parameter estimation. The algorithm integrates the Metropolis-Hastings algorithm, which
draws posterior samples by comparing posterior densities from two adjacent iterations, with
the Gibbs sampling scheme, which allows for sampling multiple model parameters within an
iteration by utilizing the full conditional likelihood. More details about the MCMC algorithm
can be found in Hoff (2009); Gelman and others (2014). Here, we show the Bayesian inference
in the frailty model. The inference of the final model we used for the LFS study can be made
by simply removing the part for the frailty estimation.
Supplementary Figure 2 shows the frailty model represented by a directed graph that
connects the observed data, model parameters and the hyper-parameter, and details about
MCMC algorithm is summarized in the following:
3
1 2
3 4 5
6 7
Supplementary Figure 1. A hypothetical pedigree to illustrate the likelihood calculation using
the Elston-Stewart algorithm. The family consists of three generations. The circle indicates
the female member while the square indicates the male. The horizontal lines indicate marriage
and vertical lines indicate the next generation. In this example, the genotype is assumed
unknown for every members except the 1st and 4th individuals.
Λ!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
Data
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!  
Supplementary Figure 2. Graphical representation of the Bayesian frailty model. Λ0 is the
cumulative baseline rate function; φ is the hyper-parameter of frailty ξ.
4
• Prior setting
β ∼ N(0, 1002); γ: flat prior; φ ∼ Gamma(.01, .01)
• Proposal setting
Given θ(t−1), generate θ∗ ∼ q(θ(t−1))
• Iterative updating:
1) Compute proposal adjustment adj = q(θ
(t−1)|θ∗)
q(θ∗|θ(t−1)) ;
2) Let h denote the cancer phenotype (or survival) data, and p(h|θ∗, others) denote
the full conditional distribution of θ∗, and compute the acceptance ratio
r = min
(
p(h|θ∗, others)p(θ∗)
p(h|θ(t−1), others)p(θ(t−1)) ∗ adj, 1
)
3) Take
θ(t) =
{
θ∗, with probability r
θ(t−1), with probability 1− r
4) Sample u ∼ Uniform(0, 1), and set θ(t) = θ∗ if u < r or θ(t) = θ(t−1) otherwise.
Since we have parameters (e.g., γ, ξ and φ) that only take positive values, we employ a
log-normal proposal. Suppose γ(t−1) ∈ (0,+∞) ∼ logN(µ, σ), and log γ(t−1) ∈ (−∞,+∞) ∼
N(µ′, σ′). To propose a new sample, we generate log γ∗ = log γ(t−1) +  where  ∼ N(0, 1),
by which we can obtain γ∗ = exp(log γ∗) ∈ (0,+∞). To adjust the asymmetric proposal
density, we calculate
adj =
lnN(γ(t−1)|lnγ∗)
lnN(γ∗|lnγ(t−1)) =
1
γ(t−1)σ
√
2pi
exp[− (lnγ(t−1)−lnγ∗)2
2σ2
]
1
γ∗σ
√
2pi
exp[− (lnγ∗−lnγ(t−1))2
2σ2
]
=
γ∗
γ(t−1)
which is simply the ratio of the proposed samples.
The posterior density for φ was constructed as previously described (Clayton, 1991). In
brief, let φ ∼ Gamma(νa, νb), or f(φ|νa, νb) = ν
νa
b
Γ{νa}φ
νa−1 exp {−νbφ}, where νa, νb are the
shape and rate of the Gamma distribution, respectively. The posterior density of φ is then
Pr(φ|ξ) ∝ Pr(ξ|φ) Pr(φ|νa, νb)
=
I∏
i
φφξ
(φ−1)
i exp(−φξi)
Γ(φ)
ννab φ
(νa−1) exp(−νbφ)
Γ(νa)
=
φIφ+νa−1 exp(−νbφ) exp
([
(φ− 1) log∏Ii ξi − φ∑Ii ξi])
Γ(φ)I
.
5
where I denotes the number of families.
Finally, we implemented this MCMC algorithm in R as follows.
To check the convergence of the algorithm, we applied the proposed models both with
and without frailty term to the real data. Supplementary Figure 3, Supplementary Figure 4,
and Supplementary Figure 5 show the results. Both models converges well and the results
are nearly identical.
6
0e+00 4e+04 8e+04
−
4
−
2
0
2
4
βG
Iteration
Es
tim
at
e
βG
Estimate
D
en
si
ty
2.5 3.0 3.5 4.0
0.
0
0.
5
1.
0
1.
5
0e+00 4e+04 8e+04
−
4
−
3
−
2
−
1
0
βS
Iteration
Es
tim
at
e
βS
Estimate
D
en
si
ty
−0.4 −0.2 0.0 0.2 0.4
0
1
2
3
0e+00 4e+04 8e+04
−
4
−
3
−
2
−
1
0
1
βG×S
Iteration
Es
tim
at
e
βG×S
Estimate
D
en
si
ty
−1.0 −0.5 0.0 0.5
0.
0
0.
5
1.
0
1.
5
0e+00 4e+04 8e+04
−
5
−
4
−
3
−
2
−
1
0
1
βD(t)
Iteration
Es
tim
at
e
βD(t)
Estimate
D
en
si
ty
−1.5 −0.5 0.0 0.5 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
0e+00 4e+04 8e+04
−
5
−
4
−
3
−
2
−
1
0
1
2
βG×D(t)
Iteration
Es
tim
at
e
βG×D(t)
Estimate
D
en
si
ty
−0.5 0.5 1.0 1.5 2.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Supplementary Figure 3. Trace plots and density distribution of posterior samples (after
removing burn-in) from the proposed method. The red line indicates posterior median esti-
mate. The density distribution is estimated based on the histogram.
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Supplementary Figure 4. Trace plots and density distribution of posterior samples (after
removing burn-in) from the frailty model. The red line indicates posterior median estimate.
The density distribution is estimated based on the histogram.
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Supplementary Figure 5. Comparison of Baseline Estimates for frailty vs. no frailty models.
D Sensitivity prior analysis
We performed sensitivity analysis by comparing penetrance estimates under different prior
settings. We tested 6 combinations of priors for β and γ: three different priors for β, including
Nomral(0, 1002), Normal(0, 102) and a flat prior, and three different priors for γ including
Gamma(0.1, 0.1) and a flat prior. Supplementary Figure 6 shows their penetrance estimates
for the first or the second primary cancers for each subgroup.
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Supplementary Figure 6. Penetrance estimates from sensitivity prior analysis for the first
(left) or the second primary cancer (right). Penetrances estimated from the different combi-
nations of prior settings are shown with the same color and line type for each subgroup.
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E Penetrance Estimates from the Frailty Model
Penetrance estimates from the frailty model and the model without frailty are shown in
Supplementary Figure 7. There is no obvious difference between the two sets of estimates.
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Supplementary Figure 7. Comparison of penetrance estimates generated from frailty model
and model without frailty.
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F Illustration of R-code
We provide estimation results for a simulated dataset with 50 families. The data gen-
eration procedure is described in Section 4. As shown in Supplementary Figure 8, our
code successfully recovers the true values of all parameters. The complete set of source
code, including the set that reproduces the results presented in this section, is available at
http://github.com/wwylab/MPC.
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Supplementary Figure 8. Our code successfully recovers the true values of all parameters.
Here (blue) solid lines represent posterior estimates and (red) dashed lines represent true
values.
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G Additional Supplementary Figures and Tables
This section contains addition figures and tables referred to in the main manuscript of this
article.
Supplementary Table 1. Summary of the LFS data referred in Section 2.1. ”W/ carriers”,
family with at least one mutation carrier; ”W/O carriers”, family with no observed mutation
carriers.
W/ carriers W/O carriers total
Number of families 17 172 189
Number of individuals 2,409 1,297 3,706
Average family size 142 8 20
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Supplementary Figure 9. Kaplan-Meier estimates of the survival distributions for the first or
the second gap times of the LFS dataset without probands, referred in Section 2.2. The solid
lines denote mutation carriers. The dotted lines denote individuals either with a wildtype or
without any genotype information. Blue denotes the first gap time W1 and pink denotes the
second gap time W2. The shaded areas are the 95% confidence bounds. A log-rank test gave
p-values < 10−7 comparing the first and second gap time distributions for individuals that
are TP53 mutation carriers, or otherwise, respectively.
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Supplementary Figure 10. Illustration of the artificial pedigree structure used for the simu-
lation study in Section 6.
Supplementary Table 2. Summary of deviance information criterion (DIC) for model selection
referred in Section 7.1. *This model is selected.
Model Covariates DIC
(M1) {G,S,D(t)} 3469.75
(M2) {G,S,D(t), G× S} 3529.36
(M3) {G,S,D(t), G×D(t)} 3526.03
(M4)* {G,S,D(t), G× S,G×D(t)} 3478.01
(M5) {G,S,D(t), G× S,G×D(t), S ×D(t)} 3499.61
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